Valuation : SANA AB

Market Cap 1.64B 173M 148M 139M 127M 239M 16.5B 240M 643M 8.32B 649M 635M 27.52B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.64B 173M 148M 139M 127M 239M 16.5B 240M 643M 8.32B 649M 635M 27.52B EV / Sales 2026 *
6.16x
EV / Sales 2027 * 4.24x
Free-Float
90.64%
Yield 2026 *
-
Yield 2027 * -
1 day+0.76%
1 week-5.48%
Current month-16.30%
1 month-9.15%
3 months-13.07%
6 months-39.17%
Current year-43.82%
1 week 11.01
Extreme 11.01
12.94
1 month 11.01
Extreme 11.01
14.46
Current year 11.01
Extreme 11.01
28.3
1 year 11
Extreme 11
28.3
3 years 1.74
Extreme 1.736
28.3
5 years 1.57
Extreme 1.572
28.3
10 years 1.57
Extreme 1.572
55
Manager TitleAgeSince
Chief Operating Officer 54 01/03/2025
Chief Executive Officer 66 30/04/2022
Chief Tech/Sci/R&D Officer 68 01/01/2014
Director TitleAgeSince
Chairman 71 30/04/2022
Director/Board Member 68 01/01/2015
Director/Board Member 46 19/01/2018
Date Insider Type Main position Quantity % Market Cap.
29/12/25 Sell

Chief Executive Officer

5,000 0.0036%
29/12/25 Sell

Chief Executive Officer

5,000 0.0036%
29/12/25 Sell

Chief Executive Officer

5,000 0.0036%
Change 5-day change 1-year change 3-year change Capi.($)
+0.76%-5.48%-15.29%+66.34% 171M
+3.31%-3.70%+61.03%+103.64% 70.42B
+1.09%+2.51%+49.34%+93.39% 65.4B
-1.03%+0.46%+8.14%-5.28% 28.28B
-2.41%-2.95%-9.77%+455.82% 27.16B
+0.59%-0.39%+63.66%+12.27% 26.57B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.37%+1.21%+36.55%-15.78% 20.09B
-0.76%-3.62%+14.21%+536.20% 15.87B
-1.50%+2.92%+43.50%+151.30% 13.9B
Average +0.11%+0.61%+52.08%+181.82% 28.85B
Weighted average by Cap. +0.75%+0.93%+56.49%+155.77%

Financials

2026 *2027 *
Net sales 267M 28.06M 24.08M 22.55M 20.65M 38.89M 2.68B 39M 104M 1.35B 105M 103M 4.47B 388M 40.75M 34.98M 32.75M 29.99M 56.49M 3.89B 56.65M 152M 1.96B 153M 150M 6.49B
Net income - -
Net Debt - -
Logo SANA AB
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Employees
43
Date Price Change Volume
27/08/26 SEK 11.91 +0.76% 685,175
26/08/26 SEK 11.82 -0.08% 477,669
25/08/26 SEK 11.83 +1.55% 174,111
24/08/26 SEK 11.65 -3.08% 293,462
21/08/26 SEK 12.02 -4.30% 1,052,306

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANION Stock